Clinical Trials Directory

Trials / Completed

CompletedNCT06582537

LAMA2 Genetic Correction

Ex Vivo Genetic Correction of LAMA2 Mutation(s) in Myogenic Stem Cells of Patients with Merosin-deficient Congenital Muscle Dystrophy Type 1a (MDC1a)

Status
Completed
Phase
Study type
Observational
Enrollment
7 (actual)
Sponsor
Maastricht University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Merosin-deficient congenital muscle dystrophy type 1a (MDC1a), or LAMA2 muscular dystrophy (LAMA2-MD) is a severe autosomal recessive form of muscular dystrophy that is caused by homozygous or compound heterozygous mutations in the laminin alpha 2 (LAMA-2) gene. Many different LAMA-2 mutations have been reported. In most cases, MDC1a is diagnosed within the first year of life, and is characterized by hypotonia, delayed motor development and white matter abnormalities. Currently, no efficient treatment is available for this patient group. Generally, MDC1a patients with mutations causing a premature stop codon are most severely affected (early onset LAMA2-MD) and patients with missense mutations are generally affected more mild affected and more late-onset (late onset LAMA2-MD). However, large variation in disease severity and clinical course is observed, even between individuals with the same mutation, e.g. the LAMA2 c.5562+5G\>C mutation, which is frequently observed in Dutch MDC1a patients. This study aims to isolate and culture fibroblasts and myogenic stem cells called mesoangioblasts from the skin and muscle biopsies of adult LAMA2 mutation carriers to explore if genetic correction of LAMA2 mutations using CRISPR-Cas9 can be achieved and subsequently assess the effect in vitro, as a first step towards therapy development.

Conditions

Interventions

TypeNameDescription
PROCEDUREParticipants sample collectionA skeletal muscle biopsy and a venous blood sample will be collected. The skin biopsy will be obtained during the incision needed for the muscle biopsy.

Timeline

Start date
2020-07-01
Primary completion
2024-07-18
Completion
2024-07-18
First posted
2024-09-03
Last updated
2024-09-03

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06582537. Inclusion in this directory is not an endorsement.